Report cover image

Top 10 Growth Opportunities in the European Life Sciences Industry, 2026

Publisher Frost & Sullivan
Published Dec 16, 2025
Length 16 Pages
SKU # MC20678789

Description

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health Data Space (EHDS) accelerate rare disease and multi-country clinical trials through harmonized procedures and interoperable patient data; the Artificial Intelligence Act (AI Act) and Biotechnology Act (Biotech Act) provide a predictable environment for AI-enabled drug discovery, multi-omics analytics, and digital quality systems; the In Vitro Diagnostic Regulation (IVDR) fuels demand for companion diagnostics and biomarker-driven precision medicine; and the Health Technology Assessment (HTA) regulation supports next-generation modalities by streamlining evidence requirements and aligning reimbursement expectations across European countries. At the manufacturing end, the EU Bioeconomy Strategy drives sustainable biomanufacturing and synthetic-biology scale-up, while the Critical Medicines Act (CMA) unlocks opportunities for nearshore active pharmaceutical ingredient (API), antimicrobial, and biosimilar production to strengthen supply chain resilience.

Europe’s ability to capture these opportunities is constrained by fragmented registries, uneven biomarker infrastructure, high-capital expenditure biomanufacturing barriers, small- and medium-sized enterprise (SME) compliance pressures, and dependency on offshore API supply. Converting regulatory momentum into competitive advantage will require targeted investment in digital-clinical infrastructure, harmonized operational frameworks, and public-private partnerships that reduce fragmentation and accelerate scale-up. By closing these structural gaps, Europe can fully realize the growth unlocked by its 2026 regulatory architecture while advancing technological sovereignty, patient-centric innovation, and resilient biomanufacturing leadership.

Table of Contents

16 Pages
Top Growth Opportunities for 2026
Strategic Imperatives
Top 10 Growth Opportunities
Growth Opportunity 1: AI-driven De Novo Drug Design and Synthesis
Growth Opportunity 2: Multi-omics Data Integration for Precision Medicine.
Growth Opportunity 3: Next-generation Biologic Modalities
Growth Opportunity 4: Strategic Nearshoring Partnerships for Biosimilar Manufacturing
Growth Opportunity 5: Life Sciences Consumer Wellness Convergence
Growth Opportunity 6: Clinical Trials for Rare Diseases
Growth Opportunity 7: Sustainable and Green Biomantufacturing
Growth Opportunity 8: AI-driven IVDR Compliance and Quality Systems
Growth Opportunity 9: Companion Diagnostic Co-development Ecosystems
Growth Opportunity 10: Resilient Antimicrobial and API Manufacturing
Top 10 Growth Opportunities
AI-Driven De Novo Drug Design and Synthesis
Multi-Omics Data Integration for Precision Medicine
Next-Generation Biologic Modalities
Strategic Nearshoring Partnerships for Biosimilar Manufacturing
Life Sciences Consumer Wellness Convergence
Clinical Trials for Rare Diseases
Sustainable and Green Biomanufacturing
AI-Driven IVDR Compliance and Quality Systems
Companion Diagnostic Co-Development Ecosystems
Resilient Antimicrobial and API Manufacturing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us